CVRx reported a significant increase in revenue for Q4 2021, driven by the successful launch of Barostim for heart failure in the United States. Total revenue was $3.7 million, a 75% increase compared to the same period in the prior year. The company is focused on driving accelerated adoption by executing on its commercial strategy, which includes the continued expansion of its salesforce and the efforts to educate healthcare providers and consumers on the benefits of Barostim.